C20orf29 Activators
C20orf29 activators encompass a diverse array of chemical compounds that target different signaling pathways, yet converge on the modulation of C20orf29 activity. Forskolin, through the elevation of cAMP levels, and Rolipram, by preventing cAMP breakdown, both enhance PKA activity, which may phosphorylate proteins that interact with C20orf29, leading to its functional enhancement. Ionomycin, by increasing intracellular calcium, and PMA, through the activation of PKC, both initiate signaling cascades that can result in the phosphorylation of proteins within the C20orf29 pathway, positively influencing its activity. These compounds, through their distinct actions, demonstrate the intricate web of cellular signaling that can be manipulated to augment the function of C20orf29.
Compounds like Isoproterenol and EGF, though different in their primary targets-the beta-adrenergic receptors and EGFR respectively-both result in the activation of kinases that can phosphorylate and enhance the function of C20orf29-associating proteins. Insulin and LY294002, acting through the insulin receptor and inhibiting PI3K respectively, trigger downstream signaling events that can lead to the activation of kinases with the potential to enhance C20orf29 activity. Calyculin A and Okadaic Acid, as inhibitors of phosphatases, ensure a sustained phosphorylation state of proteins that may be critical for the proper function of C20orf29. IBMX and Anisomycin further contribute to the enhancement of C20orf29 by increasing kinase activity through cAMP accumulation and MAPK pathway activation, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a selective PDE4 inhibitor, prevents cAMP degradation, leading to elevated PKA activity. PKA could phosphorylate associated proteins of C20orf29, thereby enhancing its activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin, by increasing intracellular calcium levels, can activate calcium-dependent kinases, which may indirectly lead to the activation of C20orf29 by phosphorylating associated proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA, through activation of PKC, can lead to phosphorylation of proteins that are part of the C20orf29 complex or pathway, thereby enhancing the functional activity of C20orf29. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, enhances cAMP levels, activating PKA, which in turn could phosphorylate and enhance the activity of proteins associated with C20orf29. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin, via its receptor, initiates a signaling cascade including PI3K/Akt that could lead to the phosphorylation of C20orf29's associated proteins, enhancing its functional activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A inhibits protein phosphatases, leading to sustained phosphorylation of proteins associated with C20orf29, which could enhance its activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, thereby increasing cAMP levels and enhancing PKA activity, which may result in the phosphorylation and activation of C20orf29-associated proteins. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin activates MAPK pathways, which can phosphorylate and enhance the functional activity of proteins that regulate or interact with C20orf29. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid, by inhibiting PP1 and PP2A phosphatases, may increase the phosphorylation state of proteins that interact with C20orf29, thereby enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, potentially causing a compensatory activation of alternate pathways that could enhance the phosphorylation and activity of C20orf29-associated proteins. | ||||||